Legato Capital Management’s Haemonetics HAE Stock Holding History

Legato Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.76M	Buy	+23,450	New	+$1.51M	0.15%	214
2026 Q1	–	Sell	-13,194	Closed	-$1.06M	–	797
2025 Q4	$1.06M	Buy	+13,194	New	+$886K	0.09%	343
2024 Q3	–	Sell	-8,088	Closed	-$669K	–	595
2024 Q2	$669K	Buy	8,088 +614	+8%	+$54K	0.09%	363
2024 Q1	$638K	Buy	7,474 +3,766	+102%	+$296K	0.08%	384
2023 Q4	$317K	Sell	3,708 -5,381	-59%	-$465K	0.04%	489
2023 Q3	$814K	Buy	9,089 +3,957	+77%	+$353K	0.12%	291
2023 Q2	$437K	Buy	5,132 +2,265	+79%	+$191K	0.06%	451
2023 Q1	$237K	Sell	2,867 -302	-10%	-$24.4K	0.04%	431
2022 Q4	$249K	Buy	+3,169	New	+$255K	0.05%	423
2018 Q1	–	Sell	-13,224	Closed	-$768K	–	160
2017 Q4	$768K	Hold	13,224	–	–	0.11%	170
2017 Q3	$593K	Hold	13,224	–	–	0.09%	190
2017 Q2	$522K	Buy	13,224 +11,888	+890%	+$488K	0.22%	119
2017 Q1	$54K	Hold	1,336	–	–	0.06%	63
2016 Q4	$53.7K	Buy	+1,336	New	+$50.4K	0.97%	48

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legato Capital Management's HAE Position: Q2 2026 in Review

Legato Capital Management opened a new position in Haemonetics (HAE) in Q2 2026: 23,450 shares worth $1.76M. The stake represents 0.15% of the portfolio and ranks #214 among its holdings. This is a return to the name: Legato Capital Management previously reported a position in HAE as recently as Q4 2025.

Legato Capital Management first reported a position in HAE in Q4 2016 and has held it in 14 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Legato Capital Management held 23,450 shares of Haemonetics worth $1.76M as of Q2 2026.
Haemonetics was a new Legato Capital Management position in Q2 2026.
Haemonetics made up 0.15% of Legato Capital Management's portfolio in Q2 2026, its #214 holding.
Legato Capital Management first reported a position in Haemonetics in Q4 2016 and has held it in 14 quarters since.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.